{"id":599906,"date":"2026-06-19T11:21:32","date_gmt":"2026-06-19T11:21:32","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/599906\/polymyalgia-rheumatica-market-is-expected-to-witness-robust-growth-by-2036-driven-by-rising-disease-burden-and-emerging-targeted-therapies-delveinsight.html"},"modified":"2026-06-19T11:21:32","modified_gmt":"2026-06-19T11:21:32","slug":"polymyalgia-rheumatica-market-is-expected-to-witness-robust-growth-by-2036-driven-by-rising-disease-burden-and-emerging-targeted-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/599906\/polymyalgia-rheumatica-market-is-expected-to-witness-robust-growth-by-2036-driven-by-rising-disease-burden-and-emerging-targeted-therapies-delveinsight.html","title":{"rendered":"Polymyalgia Rheumatica Market is Expected to Witness Robust Growth by 2036 Driven by Rising Disease Burden and Emerging Targeted Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1781847262.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Polymyalgia Rheumatica Market is Expected to Witness Robust Growth by 2036 Driven by Rising Disease Burden and Emerging Targeted Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1781847262.jpg\" alt=\"Polymyalgia Rheumatica Market is Expected to Witness Robust Growth by 2036 Driven by Rising Disease Burden and Emerging Targeted Therapies | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The Polymyalgia Rheumatica Market is expected to witness notable growth during the forecast period, driven by increasing disease prevalence, improved diagnosis rates, and rising awareness among healthcare providers and patients. The growing adoption of targeted biologics, demand for steroid-sparing treatment options, and the anticipated launch of emerging therapies are expected to enhance treatment outcomes and support market expansion across the 7MM.<\/div>\n<p style=\"text-align: justify\">DelveInsight&rsquo;s latest report, &ldquo;Polymyalgia Rheumatica Market Insights, Epidemiology, and Market Forecast&ndash;2036,&rdquo; provides a comprehensive understanding of the Polymyalgia Rheumatica market, including historical and forecasted epidemiology, current treatment practices, emerging therapies, market trends, market share, and competitive dynamics across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\">Key Takeaways from the Polymyalgia Rheumatica Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The Polymyalgia Rheumatica market size across the 7MM is expected to grow substantially between 2026 and 2036.<\/p>\n<\/li>\n<li>\n<p>DelveInsight estimates indicate that the total Polymyalgia Rheumatica market size in the 7MM was approximately USD 237.58 million in 2022 and is projected to reach nearly USD 2,729.41 million by 2036.<\/p>\n<\/li>\n<li>\n<p>In October 2025, Novartis announced that Cosentyx (secukinumab) met its primary and all secondary endpoints in the Phase III REPLENISH trial in adults with Polymyalgia Rheumatica.<\/p>\n<\/li>\n<li>\n<p>In November 2024, the EMA granted a positive opinion for extending the indication of KEVZARA (sarilumab) to include Polymyalgia Rheumatica in adults with inadequate corticosteroid response or relapse during tapering.<\/p>\n<\/li>\n<li>\n<p>The disease predominantly affects adults over 50 years of age and is more common in women than men.<\/p>\n<\/li>\n<li>\n<p>According to secondary research, the age- and gender-adjusted prevalence of Polymyalgia Rheumatica in the United States is approximately 701 cases per 100,000 individuals aged 50 years and older.<\/p>\n<\/li>\n<li>\n<p>Germany represented one of the largest patient populations within EU4 and the UK, reflecting a considerable disease burden.<\/p>\n<\/li>\n<li>\n<p>Key Polymyalgia Rheumatica companies developing novel therapies include Novartis, Regeneron, Sanofi, and others.<\/p>\n<\/li>\n<li>\n<p>Leading Polymyalgia Rheumatica drugs include KEVZARA (sarilumab) and emerging therapy Cosentyx (secukinumab).<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Keen to know more about the market? Request our sample page at:<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/polymyalgia-rheumatica-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/sample-request\/polymyalgia-rheumatica-market<\/a><\/p>\n<p style=\"text-align: justify\">Key Factors Driving the Polymyalgia Rheumatica Market Growth<\/p>\n<p style=\"text-align: justify\">Growing Aging Population and Increasing Disease Burden<\/p>\n<p style=\"text-align: justify\">Polymyalgia Rheumatica primarily affects older adults, particularly those over 50 years of age. As global populations continue to age, the number of diagnosed and treated cases is expected to rise significantly, supporting expansion of the Polymyalgia Rheumatica market.<\/p>\n<p style=\"text-align: justify\">Rising Demand for Steroid-Sparing Therapies<\/p>\n<p style=\"text-align: justify\">Although glucocorticoids remain the cornerstone of treatment, long-term use is associated with significant toxicity and frequent relapses during tapering. This has created strong demand for safer and more durable treatment options capable of reducing corticosteroid dependence.<\/p>\n<p style=\"text-align: justify\">Expansion of Targeted Biologic Treatments<\/p>\n<p style=\"text-align: justify\">The introduction of IL-6 inhibitors and the advancement of novel targeted therapies are transforming the Polymyalgia Rheumatica treatment landscape. The growing adoption of biologics and emerging immunomodulatory agents is expected to accelerate Polymyalgia Rheumatica market growth throughout the forecast period.<\/p>\n<p style=\"text-align: justify\">Polymyalgia Rheumatica Treatment Market Landscape<\/p>\n<p style=\"text-align: justify\">Current management of Polymyalgia Rheumatica focuses on reducing inflammation, relieving pain and stiffness, preventing relapses, and maintaining physical function. Glucocorticoids remain the standard first-line treatment, while methotrexate and leflunomide are commonly used as steroid-sparing agents in selected patients.<\/p>\n<p style=\"text-align: justify\">Among approved targeted therapies, KEVZARA (sarilumab) is currently the only biologic specifically approved for Polymyalgia Rheumatica. The therapy targets the IL-6 receptor and is indicated for adults who experience inadequate response to corticosteroids or difficulty tapering treatment.<\/p>\n<p style=\"text-align: justify\">Despite these advances, substantial unmet need persists due to high relapse rates, prolonged treatment duration, and limited availability of durable steroid-sparing therapies.<\/p>\n<p style=\"text-align: justify\">Discover more about therapies set to grab major Polymyalgia Rheumatica market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/polymyalgia-rheumatica-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">Polymyalgia Rheumatica Treatment Landscape<\/a><\/p>\n<p style=\"text-align: justify\">Emerging Polymyalgia Rheumatica DrugsKEVZARA (Sarilumab): Regeneron\/Sanofi<\/p>\n<p style=\"text-align: justify\">KEVZARA is the first approved biologic therapy specifically indicated for Polymyalgia Rheumatica. By targeting the IL-6 receptor, it provides a steroid-sparing treatment option for patients experiencing relapsing or refractory disease. The FDA approved KEVZARA for Polymyalgia Rheumatica in February 2023 following positive Phase III clinical trial outcomes.<\/p>\n<p style=\"text-align: justify\">Cosentyx (Secukinumab): Novartis<\/p>\n<p style=\"text-align: justify\">Cosentyx is a fully human biologic targeting IL-17A and is being investigated as a novel treatment option for Polymyalgia Rheumatica. In October 2025, the Phase III REPLENISH study demonstrated statistically significant sustained remission and reduced corticosteroid exposure compared with placebo. Regulatory submissions are expected to follow, positioning Cosentyx as a potential paradigm-shifting therapy in the Polymyalgia Rheumatica drug market.<\/p>\n<p style=\"text-align: justify\">Recent Developments in the Polymyalgia Rheumatica Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Novartis reported positive Phase III REPLENISH trial results for Cosentyx in October 2025.<\/p>\n<\/li>\n<li>\n<p>Regulatory submissions for Cosentyx in Polymyalgia Rheumatica are expected in the first half of 2026.<\/p>\n<\/li>\n<li>\n<p>The EMA granted a positive opinion supporting expansion of KEVZARA&rsquo;s indication to Polymyalgia Rheumatica in Europe.<\/p>\n<\/li>\n<li>\n<p>Increasing focus on targeted immunomodulation and disease-specific biologics is expected to reshape future Polymyalgia Rheumatica treatment trends.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">What is Polymyalgia Rheumatica?<\/p>\n<p style=\"text-align: justify\">Polymyalgia Rheumatica (PMR) is a chronic inflammatory rheumatic disorder characterized by rapid-onset bilateral pain and stiffness affecting the shoulders, neck, and hips. The condition primarily affects adults older than 50 years and is frequently associated with elevated inflammatory markers such as ESR and CRP. PMR shares a close relationship with Giant Cell Arteritis and is often considered part of the same inflammatory disease spectrum.<\/p>\n<p style=\"text-align: justify\">Polymyalgia Rheumatica Epidemiology Segmentation<\/p>\n<p style=\"text-align: justify\">The epidemiology section of the report provides detailed insights into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Prevalent Cases of Polymyalgia Rheumatica<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Prevalent Cases of Polymyalgia Rheumatica<\/p>\n<\/li>\n<li>\n<p>Gender-specific Cases of Polymyalgia Rheumatica<\/p>\n<\/li>\n<li>\n<p>Treated Cases of Polymyalgia Rheumatica<\/p>\n<\/li>\n<li>\n<p>Country-specific Epidemiology Analysis<\/p>\n<\/li>\n<li>\n<p>Forecasted Patient Population Trends<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Scope of the Polymyalgia Rheumatica Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Comprehensive assessment of the Polymyalgia Rheumatica market size, share, trends, and forecast<\/p>\n<\/li>\n<li>\n<p>Detailed epidemiology analysis across the 7MM<\/p>\n<\/li>\n<li>\n<p>Evaluation of current and emerging Polymyalgia Rheumatica treatments<\/p>\n<\/li>\n<li>\n<p>Analysis of marketed and pipeline Polymyalgia Rheumatica drugs<\/p>\n<\/li>\n<li>\n<p>Competitive intelligence and SWOT analysis<\/p>\n<\/li>\n<li>\n<p>Market access and reimbursement assessment<\/p>\n<\/li>\n<li>\n<p>KOL perspectives and analyst insights<\/p>\n<\/li>\n<li>\n<p>Country-wise market forecasts through 2036<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">To know more about Polymyalgia Rheumatica companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/polymyalgia-rheumatica-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">Polymyalgia Rheumatica Clinical Trials and Therapeutic Assessment<\/a>Table of Contents<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>Polymyalgia Rheumatica Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Disease Background and Overview<\/p>\n<\/li>\n<li>\n<p>Signs and Symptoms<\/p>\n<\/li>\n<li>\n<p>Diagnosis and Diagnostic Guidelines<\/p>\n<\/li>\n<li>\n<p>Treatment and Management<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Patient Journey<\/p>\n<\/li>\n<li>\n<p>Marketed Drugs<\/p>\n<\/li>\n<li>\n<p>KEVZARA (Sarilumab): Detailed Assessment<\/p>\n<\/li>\n<li>\n<p>Emerging Drugs<\/p>\n<\/li>\n<li>\n<p>Cosentyx (Secukinumab): Detailed Assessment<\/p>\n<\/li>\n<li>\n<p>Polymyalgia Rheumatica Market Analysis<\/p>\n<\/li>\n<li>\n<p>Market Outlook<\/p>\n<\/li>\n<li>\n<p>Market Size by Therapies<\/p>\n<\/li>\n<li>\n<p>Country-wise Market Forecast<\/p>\n<\/li>\n<li>\n<p>KOL Views<\/p>\n<\/li>\n<li>\n<p>Unmet Needs<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>Report Methodology<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">About DelveInsight<\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=polymyalgia-rheumatica-market-is-expected-to-witness-robust-growth-by-2036-driven-by-rising-disease-burden-and-emerging-targeted-therapies-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=polymyalgia-rheumatica-market-is-expected-to-witness-robust-growth-by-2036-driven-by-rising-disease-burden-and-emerging-targeted-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Polymyalgia Rheumatica Market is expected to witness notable growth during the forecast period, driven by increasing disease prevalence, improved diagnosis rates, and rising awareness among healthcare providers and patients.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/599906"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=599906"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/599906\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=599906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=599906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=599906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}